Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$3.38 - $4.58 $71,963 - $97,512
21,291 Added 110.57%
40,547 $171,000
Q4 2023

Feb 08, 2024

SELL
$3.38 - $4.58 $102,393 - $138,746
-30,294 Reduced 61.14%
19,256 $40.5 Million
Q4 2022

Feb 06, 2023

BUY
$6.87 - $10.96 $132,288 - $211,045
19,256 Added 63.56%
49,550 $366,000
Q3 2022

Dec 01, 2022

BUY
$9.44 - $11.76 $228,872 - $285,121
24,245 Added 400.81%
30,294 $300,000
Q3 2022

Oct 26, 2022

BUY
$9.44 - $11.76 $228,872 - $285,121
24,245 Added 400.81%
30,294 $300,000
Q4 2021

Dec 01, 2022

SELL
$15.69 - $21.14 $311,540 - $419,755
-19,856 Reduced 76.65%
6,049 $95,000
Q4 2021

Jan 31, 2022

SELL
$15.69 - $21.14 $311,540 - $419,755
-19,856 Reduced 76.65%
6,049 $95,000
Q3 2021

Dec 01, 2022

SELL
$15.35 - $21.27 $67,371 - $93,354
-4,389 Reduced 14.49%
25,905 $444,000
Q3 2021

Oct 20, 2021

BUY
$15.35 - $21.27 $397,641 - $550,999
25,905 New
25,905 $444,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $265M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Robeco Institutional Asset Management B.V. Portfolio

Follow Robeco Institutional Asset Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Robeco Institutional Asset Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Robeco Institutional Asset Management B.V. with notifications on news.